Three Recent Shifts in Type 1 Diabetes: What You Should Know

From a new insulin option to expanded CGM coverage and device research, the Type 1 diabetes landscape is evolving. Here's what changed this August.

Video report — unverified, pending corroboration

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

living with t1dtechnologysupport

Key takeaways

The FDA approved Garzulys, a new rapid-acting insulin biosimilar that works like NovoLog, offering another option for people using mealtime insulin.
Hawai'i enacted a law requiring insurers—including Medicaid managed care plans—to cover continuous glucose monitors, expanding access to CGM technology.
A new clinical trial is directly comparing Omnipod 6 and Omnipod 5 to help people and clinicians understand how the newer system performs.

A New Rapid-Acting Insulin Biosimilar

On July 30, the FDA approved Garzulys (insulin aspart-fsan), a biosimilar to NovoLog, developed by Meitheal Pharmaceuticals. A biosimilar is a medication designed to work the same way as an existing approved drug but made using a different manufacturing process.

For people with Type 1 diabetes who use rapid-acting mealtime insulin, this approval adds another option to the market. Like NovoLog, Garzulys is meant to help manage blood sugar spikes after meals. If you're considering any insulin change, talk with your healthcare team first—they can help determine what's right for your specific situation.

Hawai'i Expands CGM Coverage

On August 5, Hawai'i enacted Senate Bill 3045, requiring insurers—including Medicaid managed care plans—to cover continuous glucose monitors. This is a meaningful step toward broader access to CGM technology, a tool that many people find helps them understand and manage their blood sugar patterns.

The law reflects growing recognition that CGMs can be important for Type 1 diabetes management. If you live in Hawai'i and have questions about your coverage options, check with your insurance plan or healthcare provider about what's now available to you.

New Trial Compares Omnipod 6 and Omnipod 5

Insulet, the company behind the Omnipod family of automated insulin pumps, has launched a randomized clinical trial comparing Omnipod 6 with Omnipod 5. The trial, registered on ClinicalTrials.gov, uses a cross-over design, meaning participants will use both systems during the study.

Head-to-head comparisons like this one can help people, families, and care teams understand how different devices perform in real-world use. If you're interested in learning more about this research or wondering whether you might be eligible to participate, ask your healthcare provider or visit ClinicalTrials.gov for details.

Evidence label

Origin: T1D Pulse (Video report). Evidence: Video report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.